Andrew N J Tutt
Overview
Explore the profile of Andrew N J Tutt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
10490
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haider S, Brough R, Madera S, Iacovacci J, Gulati A, Wicks A, et al.
Nat Genet
. 2025 Mar;
57(3):522-529.
PMID: 40033056
To maintain cell fitness, deleterious genetic alterations are buffered by compensatory changes in additional genes. In cancer, buffering processes could be targeted by synthetic lethality. However, despite the large-scale identification...
2.
Stewart J, Krastev D, Brough R, Zatreanu D, Song F, Baxter J, et al.
Oncogene
. 2025 Feb;
44(9):618-629.
PMID: 39939726
Identification of ARID1A/ATR synthetic lethality led to ATR inhibitor phase II trials in ovarian clear cell carcinoma (OCCC), a cancer of unmet need. Using multiple CRISPR-Cas9 mutagenesis and interference screens,...
3.
Cheung A, Chenoweth A, Johansson A, Laddach R, Guppy N, Trendell J, et al.
Clin Cancer Res
. 2024 May;
30(15):3298-3315.
PMID: 38772416
Purpose: Anti-EGFR antibodies show limited response in breast cancer, partly due to activation of compensatory pathways. Furthermore, despite the clinical success of cyclin-dependent kinase (CDK) 4/6 inhibitors in hormone receptor-positive...
4.
Ganz P, Bandos H, Spanic T, Friedman S, Muller V, Kuemmel S, et al.
J Clin Oncol
. 2024 Feb;
42(11):1288-1300.
PMID: 38301187
Purpose: The OlympiA randomized phase III trial compared 1 year of olaparib (OL) or placebo (PL) as adjuvant therapy in patients with germline , high-risk human epidermal growth factor receptor...
5.
Fitzpatrick A, Iravani M, Mills A, Vicente D, Alaguthurai T, Roxanis I, et al.
Nat Commun
. 2023 Nov;
14(1):7408.
PMID: 37973922
Breast cancer leptomeningeal metastasis (BCLM), where tumour cells grow along the lining of the brain and spinal cord, is a devastating development for patients. Investigating this metastatic site is hampered...
6.
Baxter J, Brough R, Krastev D, Song F, Sridhar S, Gulati A, et al.
Mol Oncol
. 2023 Oct;
18(2):369-385.
PMID: 37866880
The F-box and WD repeat domain containing 7 (FBXW7) tumour suppressor gene encodes a substrate-recognition subunit of Skp, cullin, F-box (SCF)-containing complexes. The tumour-suppressive role of FBXW7 is ascribed to...
7.
Pettitt S, Shao N, Zatreanu D, Frankum J, Bajrami I, Brough R, et al.
Oncogene
. 2023 Jul;
42(36):2701-2709.
PMID: 37491606
Although PARP inhibitors (PARPi) now form part of the standard-of-care for the treatment of homologous recombination defective cancers, de novo and acquired resistance limits their overall effectiveness. Previously, overexpression of...
8.
Zelceski A, Francica P, Lingg L, Mutlu M, Stok C, Liptay M, et al.
Cell Rep
. 2023 May;
42(5):112484.
PMID: 37163373
The PSMC3IP-MND1 heterodimer promotes meiotic D loop formation before DNA strand exchange. In genome-scale CRISPR-Cas9 mutagenesis and interference screens in mitotic cells, depletion of PSMC3IP or MND1 causes sensitivity to...
9.
Harvey-Jones E, Lord C, Tutt A
Hematol Oncol Clin North Am
. 2022 Nov;
37(1):203-224.
PMID: 36435611
Approximately 5% to 10% of all breast cancers are hereditary; many of which are caused by pathogenic variants in genes required for homologous recombination, including BRCA1 and BRCA2. Here we...
10.
Wicks A, Krastev D, Pettitt S, Tutt A, Lord C
Open Biol
. 2022 Jul;
12(7):220118.
PMID: 35892198
PARP inhibitors (PARPi) have been demonstrated to exhibit profound anti-tumour activity in individuals whose cancers have a defect in the homologous recombination DNA repair pathway. Here, we describe the current...